|
1
|
Lazaridis KN and Gores GJ:
Cholangiocarcinoma. Gastroenterology. 128:1655–1667. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Keane MG, Horsfall L, Rait G and Pereira
SP: A case-control study comparing the incidence of early symptoms
in pancreatic and biliary tract cancer. BMJ Open. 4:e0057202014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khan SA, Emadossadaty S, Ladep NG, Thomas
HC, Elliott P, Taylor-Robinson SD and Toledano MB: Rising trends in
cholangiocarcinoma: Is the ICD classification system misleading us?
J Hepatol. 56:848–854. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Randi G, Malvezzi M, Levi F, Ferlay J,
Negri E, Franceschi S and La Vecchia C: Epidemiology of biliary
tract cancers: An update. Ann Oncol. 20:146–159. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsuda T and Marugame T: International
comparisons of cumulative risk of gallbladder cancer and other
biliary tract cancer, from Cancer Incidence in Five Continents Vol.
VIII. Jpn J Clin Oncol. 37:74–75. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Taylor-Robinson SD, Toledano MB, Arora S,
Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P and Thomas HC:
Increase in mortality rates from intrahepatic cholangiocarcinoma in
England and Wales 1968–1998. Gut. 48:816–820. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Patel T: Increasing incidence and
mortality of primary intrahepatic cholangiocarcinoma in the United
States. Hepatology. 33:1353–1357. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khan SA, Taylor-Robinson SD, Toledano MB,
Beck A, Elliott P and Thomas HC: Changing international trends in
mortality rates for liver, biliary and pancreatic tumours. J
Hepatol. 37:806–813. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Malka D, Cervera P, Foulon S, Trarbach T,
de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF,
Viret F, et al: Gemcitabine and oxaliplatin with or without
cetuximab in advanced biliary-tract cancer (BINGO): A randomised,
open-label, non-comparative phase 2 trial. Lancet Oncol.
15:819–828. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: Cisplatin plus gemcitabine versus gemcitabine for
biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eckel F and Schmid RM: Chemotherapy in
advanced biliary tract carcinoma: A pooled analysis of clinical
trials. Br J Cancer. 96:896–902. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sharma A, Dwary AD, Mohanti BK, Deo SV,
Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P and
Chaudhary SP: Best supportive care compared with chemotherapy for
unresectable gall bladder cancer: A randomized controlled study. J
Clin Oncol. 28:4581–4586. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Awasthi YC, Chaudhary P, Vatsyayan R,
Sharma A, Awasthi S and Sharma R: Physiological and pharmacological
significance of glutathione-conjugate transport. J Toxicol Environ
Health B Crit Rev. 12:540–551. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang W, Sun YP, Huang XZ, He M, Chen YY,
Shi GY, Li H, Yi J and Wang J: Emodin enhances sensitivity of
gallbladder cancer cells to platinum drugs via glutathion depletion
and MRP1 downregulation. Biochem Pharmacol. 79:1134–1140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Omar JM, Yang H, Li S, Marquardt RR and
Jones PJ: Development of an improved reverse-phase high-performance
liquid chromatography method for the simultaneous analyses of
trans-/cis-resveratrol, quercetin and emodin in commercial
resveratrol supplements. J Agric Food Chem. 62:5812–5817. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Srinivas G, Babykutty S, Sathiadevan PP
and Srinivas P: Molecular mechanism of emodin action: Transition
from laxative ingredient to an antitumor agent. Med Res Rev.
27:591–608. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu JD, Wang W, Li LS, Chen X and Zhu JX:
Involvement of endogenous prostaglandin in emodin-evoked rat
colonic anion secretion. Biol Pharm Bull. 30:2058–2062. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Anderson CP, Tsai JM, Meek WE, Liu RM,
Tang Y, Forman HJ and Reynolds CP: Depletion of glutathione by
buthionine sulfoxine is cytotoxic for human neuroblastoma cell
lines via apoptosis. Exp Cell Res. 246:183–192. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bailey HH, Ripple G, Tutsch KD,
Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun
M, Mulcahy RT and Wilding G: Phase I study of continuous-infusion
L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl
Cancer Inst. 89:1789–1796. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bailey HH, Mulcahy RT, Tutsch KD,
Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M and
Spriggs DR: Phase I clinical trial of intravenous L-buthionine
sulfoximine and melphalan: An attempt at modulation of glutathione.
J Clin Oncol. 12:194–205. 1994.PubMed/NCBI
|
|
21
|
O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo
JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J,
Young RC, et al: Phase I trial of buthionine sulfoximine in
combination with melphalan in patients with cancer. J Clin Oncol.
14:249–256. 1996.PubMed/NCBI
|
|
22
|
Jia Y, Zhang W, Liu H, Peng L, Yang Z and
Lou J: Inhibition of glutathione synthesis reverses Krüppel-like
factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol.
69:377–385. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tagde A, Singh H, Kang MH and Reynolds CP:
The glutathione synthesis inhibitor buthionine sulfoximine
synergistically enhanced melphalan activity against preclinical
models of multiple myeloma. Blood Cancer J. 4:e2292014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hernandez-Breijo B, Monserrat J,
Ramirez-Rubio S, Cuevas EP, Vara D, Díaz-Laviada I,
Fernández-Moreno MD, Román ID, Gisbert JP and Guijarro LG:
Preclinical evaluation of azathioprine plus buthionine sulfoximine
in the treatment of human hepatocarcinoma and colon carcinoma.
World J Gastroenterol. 17:3899–3911. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chowdhury AA, Chaudhuri J, Biswas N, Manna
A, Chatterjee S, Mahato SK, Chaudhuri U, Jaisankar P and
Bandyopadhyay S: Synergistic apoptosis of CML cells by buthionine
sulfoximine and hydroxychavicol correlates with activation of AIF
and GSH-ROS-JNK-ERK-iNOS pathway. PloS one. 8:e736722013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yi J, Yang J, He R, Gao F, Sang H, Tang X
and Ye RD: Emodin enhances arsenic trioxide-induced apoptosis via
generation of reactive oxygen species and inhibition of survival
signaling. Cancer Res. 64:108–116. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jing Y, Yang J, Wang Y, Li H, Chen Y, Hu
Q, Shi G, Tang X and Yi J: Alteration of subcellular redox
equilibrium and the consequent oxidative modification of nuclear
factor kappaB are critical for anticancer cytotoxicity by emodin, a
reactive oxygen species-producing agent. Free Radic Biol Med.
40:2183–2197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zitka O, Skalickova S, Gumulec J, Masarik
M, Adam V, Hubalek J, Trnkova L, Kruseova J, Eckschlager T and
Kizek R: Redox status expressed as GSH:GSSG ratio as a marker for
oxidative stress in paediatric tumour patients. Oncol Lett.
4:1247–1253. 2012.PubMed/NCBI
|
|
29
|
Rahman I, Kode A and Biswas SK: Assay for
quantitative determination of glutathione and glutathione disulfide
levels using enzymatic recycling method. Nat Protoc. 1:3159–3165.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fan J, Cai H, Yang S, Yan L and Tan W:
Comparison between the effects of normoxia and hypoxia on
antioxidant enzymes and glutathione redox state in ex vivo culture
of CD34(+) cells. Comp Biochem Physiol B Biochem Mol Biol.
151:153–158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Han Y, Huang C, Sun X, Xiang B, Wang M,
Yeh ET, Chen Y, Li H, Shi G, Cang H, et al: SENP3-mediated
de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated
with accelerated cell proliferation under mild oxidative stress. J
Biol Chem. 285:12906–12915. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liaudat AC, Bohl LP, de Talamoni Tolosa
NG, Maletto B, Pistoresi-Palencia MC and Picotto G: Oxidative
stress, cell cycle arrest and differentiation contribute toward the
antiproliferative action of BSO and calcitriol on Caco-2 cells.
Anticancer Drugs. 25:810–818. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hadzic T, Aykin-Burns N, Zhu Y, Coleman
MC, Leick K, Jacobson GM and Spitz DR: Paclitaxel combined with
inhibitors of glucose and hydroperoxide metabolism enhances breast
cancer cell killing via H2O2-mediated oxidative stress. Free Radic
Biol Med. 48:1024–1033. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schnelldorfer T, Gansauge S, Gansauge F,
Schlosser S, Beger HG and Nussler AK: Glutathione depletion causes
cell growth inhibition and enhanced apoptosis in pancreatic cancer
cells. Cancer. 89:1440–1447. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rudin CM, Yang Z, Schumaker LM,
VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG and Cullen KJ:
Inhibition of glutathione synthesis reverses Bcl-2-mediated
cisplatin resistance. Cancer Res. 63:312–318. 2003.PubMed/NCBI
|
|
36
|
Meurette O, Lefeuvre-Orfila L, Rebillard
A, Lagadic-Gossmann D and Dimanche-Boitrel MT: Role of
intracellular glutathione in cell sensitivity to the apoptosis
induced by tumor necrosis factor {alpha}-related apoptosis-inducing
ligand/anticancer drug combinations. Clin Cancer Res. 11:3075–3083.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Buolamwini JK: Novel anticancer drug
discovery. Curr Opin Chem Biol. 3:500–509. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu WJ, Zhang Y, Zeng ZL, Li XB, Hu KS, Luo
HY, Yang J, Huang P and Xu RH: β-phenylethyl isothiocyanate
reverses platinum resistance by a GSH-dependent mechanism in cancer
cells with epithelial-mesenchymal transition phenotype. Biochem
Pharmacol. 85:486–496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ishikawa T and Ali-Osman F:
Glutathione-associated cis-diamminedichloroplatinum (II) metabolism
and ATP-dependent efflux from leukemia cells. Molecular
characterization of glutathione-platinum complex and its biological
significance. J Biol Chem. 268:20116–20125. 1993.PubMed/NCBI
|
|
40
|
Sorensen BH, Thorsteinsdottir UA and
Lambert IH: Acquired cisplatin resistance in humane ovarian cancer
A2780 cells correlates with shift in taurine homeostasis and
ability to volume regulate. Am J Physiol Cell Physiol.
307:C1071–C1080. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Heiser D, Labi V, Erlacher M and Villunger
A: The Bcl-2 protein family and its role in the development of
neoplastic disease. Exp Gerontol. 39:1125–1135. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Butturini E, de Prati Carcereri A,
Chiavegato G, Rigo A, Cavalieri E, Darra E and Mariotto S: Mild
oxidative stress induces S-glutathionylation of STAT3 and enhances
chemosensitivity of tumoural cells to chemotherapeutic drugs. Free
Radic Biol Med. 65:1322–1330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lu Z, Wang J, Zheng T, Liang Y, Yin D,
Song R, Pei T, Pan S, Jiang H and Liu L: FTY720 inhibits
proliferation and epithelial-mesenchymal transition in
cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer.
14:7832014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Deng H, Zhou Z, Tu W, Xia Y, Huang H and
Tian D: Knockdown of astrocyte elevated gene-1 inhibits growth
through suppression of IL-6 secretion in HepG2 human hepatoma
cells. Oncol Lett. 7:101–106. 2014.PubMed/NCBI
|
